17
ALL1
Alembic Pharmaceuticals Limited1
Biocon1
Exemed Pharmaceuticals1
Glenmark Pharmaceuticals1
Lupin Ltd9
Novartis Pharmaceuticals Corporation1
Prague Scientific1
USV Private Limited1
Zydus LifesciencesYear
17
ALL7
20243
20231
20224
20212
2020DEALS // DEV.
17
ALL2
Deals15
DevelopmentsCountry
17
ALL1
CZECH REPUBLIC7
INDIA9
SWITZERLAND17
ALL1
Dr. Reddy's Laboratories13
Not Applicable1
Otsuka Chemical Co Ltd2
Otsuka PharmaceuticalTherapeutic Area
17
ALL13
Cardiology/Vascular Diseases4
TechnologyStudy Phase
17
ALL16
Approved1
Phase IIIDeal Type
2
ALL2
AgreementProduct Type
17
ALL17
Small moleculeDosage Form
11
ALL2
Film-Coated Tablet3
Film-coated Tablet1
Film-coated tablet3
Tablet2
Tablet, Film CoatedLead Product
17
ALL17
Sacubitril SodiumTarget
6
ALL6
NeprilysinLead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
USV Introduces OnArni, FDC of Sacubitril, Valsartan, For HF Management
Details : OnArni (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.
Brand Name : OnArni
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 15, 2024
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Exemed Receives CDSCO Nod For Study of Sacubitril Plus Valsartan Sustained-Release Tablet
Details : Sacubright (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.
Brand Name : Sacubright
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 04, 2024
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biocon Unit Gets USFDA Nod For Generic Drug
Details : Sacubitril and valsartan is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.
Brand Name : Entresto-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 02, 2024
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zydus Lifesciences gets USFDA nod to market chronic heart failure treatment drug
Details : Enresto-Generic (sacubitril and valsartan) is an oral neprilysin inhibitor, is approved for the treatment of additional indication of adults chronic heart failure.
Brand Name : Entresto-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 10, 2024
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Alembic Pharmaceuticals receives USFDA final approval for Sacubitril and Valsartan Tablets
Details : A eneric formulation of sacubitril and valsartan, an oral neprilysin inhibitor, is approved for the treatment of additional indication of adults chronic heart failure.
Brand Name : Entresto-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 29, 2024
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Otsuka Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis Gets Japan Approval for Entresto Granular Tablets for Pediatric Heart Failure Use
Details : Entresto (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of additional indication of pediatric chronic heart failure.
Brand Name : Entresto
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 26, 2024
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Otsuka Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Otsuka Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis Gains Approval for Entresto for Pediatric Chronic Heart Failure
Details : Entresto (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of additional indication of pediatric chronic heart failure.
Brand Name : Entresto
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 09, 2024
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Otsuka Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis Entresto Receives Positive CHMP Opinion for Pediatric Heart Failure
Details : Entresto contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. It inhibits neprilysin via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 receptor via valsartan in pedia...
Brand Name : Entresto
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 31, 2023
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients
Details : Sacubitril and Valsartan drug inhibits neprilysin and blocks angiotensin II type-I receptor, increasing the levels of peptides degraded by neprilysin. It is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure.
Brand Name : Valentas
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 18, 2023
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Glenmark Launches Drug to Treat Heart Failure
Details : Sacubitril and Valsartan drug inhibits neprilysin and blocks angiotensin II type-I receptor, increasing the levels of peptides degraded by neprilysin. It is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure.
Brand Name : Sacu V
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 17, 2023
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?